Highlights
- •Cholesterol biomarkers association with serum neurofilaments in MS were studied.
- •Serum neurofilaments were associated with apolipoprotein E at 5-year follow-up.
- •Apolipoprotein E4 allele was associated with greater serum neurofilaments.
- •Increased HDL associated with less gray matter and cortical atrophy.
- •Cholesterol biomarkers associations remain after adjusting for serum neurofilaments.
Abstract
Purpose To investigate the associations between longitudinal changes in lipid biomarkers
and serum neurofilament (sNfL) levels in multiple sclerosis (MS) neurodegeneration
and disease progression.
Methods 5-year prospective, longitudinal study included 75 relapsing-remitting MS
(RR-MS) and 37 progressive-MS (P-MS) patients. sNfL, plasma total cholesterol (TC),
high-density (HDL-C) and low-density (LDL-C) lipoprotein cholesterol, apolipoproteins
(Apo), ApoA-I, Apo-II, ApoB, ApoC-II and ApoE were measured at baseline and 5-years.
Annual percent changes in whole brain volume (PBVC), gray matter volume (PGMVC) and
cortical volume (PCVC) were obtained from MRI at baseline and 5-years.
Results sNfL levels at 5-year follow-up were associated with ApoE at follow-up (p = 0.014), age at follow-up, body mass index (p < 0.001) and RR vs. P-MS status at follow-up. APOE4 allele was associated with greater sNfL levels at 5-years (p = 0.022) and pronounced in the P-MS group. PGMVC and PCVC were associated with percent
changes in HDL-C (p = 0018 and p < 0.001, respectively) and ApoA-I (p = 0.0073 and p = 0.006). PGMVC and PCVC remained associated with percent change in HDL-C (p = 0.0024 and p < 0.001, respectively) after sNfL was included as a predictor.
Conclusions HDL-C percent change is associated with decreased gray matter atrophy
after adjusting for baseline sNfL.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Multiple Sclerosis and Related DisordersAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis.Brain. 2018;
- Risk factors for and management of cognitive dysfunction in multiple sclerosis.Nat. Rev. Neurol. 2011; 7: 332-342
- ApoE production in human monocytes and its regulation by inflammatory cytokines.PLoS ONE. 2013; 8: e79908
- Apolipoproteins are associated with new MRI lesions and deep grey matter atrophy in clinically isolated syndromes.J. Neurol. Neurosurg. Psychiatry. 2014; 85: 859-864
- High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation.Autoimmun. Rev. 2002; 1: 111-117
- A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis.Mol. Cell. 2001; 7: 161-171
- Blood cholesterol screening influence of fasting state on cholesterol results and management decisions.J. Gen. Intern. Med. 2000; 15: 395-399
- Serum neurofilament light chain levels are increased in patients with a clinically isolated syndrome.J. Neurol. Neurosurg. Psychiatr. 2016; 87: 126-129
- Serum neurofilament light: a biomarker of neuronal damage in multiple sclerosis.Ann. Neurol. 2017; 81: 857-870
- Cholesterol level correlate with disability score in patients with relapsing-remitting form of multiple sclerosis.Neurosci. Lett. 2018; 687: 304-307
- Isoform-specific proteolysis of apolipoprotein-E in the brain.Neurobiol. Aging. 2011; 32: 257-271
- Apolipoproteins in the brain: implications for neurological and psychiatric disorders.Clin. Lipidol. 2010; 51: 555-573
- Cognitive and neuropsychiatric disease manifestations in MS.Mult. Scler. Relat. Disord. 2013; 2: 4-12
- Oxysterols and apolipoproteins in multiple sclerosis: a 5 year follow-up study.J. Lipid Res. 2019; 60: 1190-1198
- Protective associations of HDL with blood-brain barrier injury in multiple sclerosis patients.J. Lipid Res. 2015; 56: 2010-2018
- Multiple sclerosis–the plaque and its pathogenesis.N. Engl. J. Med. 2006; 354: 942-955
- Measurement and clinical effect of grey matter pathology in multiple sclerosis.Lancet Neurol. 2012; 11: 1082-1092
- Introduction to Mediation, Moderation, and Conditional Process Analysis : a Regression-Based Approach.Second edition. Guilford Press, New York2018: 692 (xx)
- HDL and cognition in neurodegenerative disorders.Neurobiol. Dis. 2014; 72: 22-36
- Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study.Ann. Clin. Transl. Neurol. 2019; 6: 1757-1770
- Walking disability measures in multiple sclerosis patients: correlations with MRI-derived global and microstructural damage.J. Neurol. Sci. 2018; 393: 128-134
- Defining the clinical course of multiple sclerosis: the 2013 revisions.Neurology. 2014; 83: 278-286
- Neurofilament light chain and oligoclonal bands are prognostic biomarkers in radiologically isolated syndrome.Brain. 2018; 141: 1085-1093
- Fasting compared with nonfasting lipids and apolipoproteins for predicting incident cardiovascular events.Circulation. 2008; 118: 993-1001
- Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow-up.Eur. J. Neurol. 2019; 27: 188-e4
- SPSS and SAS procedures for estimating indirect effects in simple mediation models.Behav. Res. Methods Instrum. Comput. 2004; 36: 717-731
- Impact of apolipoprotein E (ApoE) polymorphism on brain ApoE levels.J. Neurosci. 2008; 28: 11445-11453
- Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS. Multiple Sclerosis Collaborative Research Group.Neurology. 1999; 53: 1698-1704
- Fasting time and lipid levels in a community-based population: a cross-sectional study.Arch. Intern. Med. 2012; 172: 1707-1710
- Serum neurofilament light chain is a biomarker of acute and chronic neuronal damage in early multiple sclerosis.Mult. Scler. 2018; 25 (1352458518765666): 678-686
- Apolipoprotein E: high-avidity binding to beta-amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer disease.Proc. Natl. Acad. Sci. 1993; 90: 1977-1981
- An adverse lipid profile is associated with disability and progression in disability, in people with MS.Mult. Scler. 2014; 20: 1737-1744
- Apolipoprotein-mediated pathways of lipid antigen presentation.Nature. 2005; 437: 906-910
- Role of lipoproteins and inflammation in cognitive decline: do they interact.Neurobiol. Aging. 2012; 33 (e1-12)
- Low HDL cholesterol is associated with lower gray matter volume in cognitively healthy adults.Front. Aging Neurosci. 2010; : 2
- Serum lipid profiles are associated with disability and MRI outcomes in multiple sclerosis.J. Neuroinflamm. 2011; 8: 127
Zhornitsky S., McKay K.A., Metz L.M., Teunissen C.E. and Rangachari M. Cholesterol and markers of cholesterol turnover in multiple sclerosis: relationship with disease outcomes. 2016; 5: 53–65.
Article info
Publication history
Published online: July 11, 2020
Accepted:
July 7,
2020
Received in revised form:
June 3,
2020
Received:
April 14,
2020
Identification
Copyright
© 2020 Elsevier B.V. All rights reserved.
